BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35483594)

  • 1. In silico, synthesis and anticancer evaluation of benzamide tryptamine derivatives as novel eEF2K inhibitors.
    Liu Z; Jiang A; Wang Y; Xu P; Zhang Q; Wang Y; He S; Wang N; Jin H; Zhang B
    Bioorg Med Chem Lett; 2022 Jul; 67():128759. PubMed ID: 35483594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
    Onder FC; Durdagi S; Kahraman N; Uslu TN; Kandemir H; Atici EB; Ozpolat B; Ay M
    Bioorg Chem; 2021 Nov; 116():105296. PubMed ID: 34488125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
    Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
    Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
    Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
    Karakas D; Ozpolat B
    J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
    Feng J; Fang H; Wang X; Jia Y; Zhang L; Jiao J; Zhang J; Gu L; Xu W
    Cancer Biol Ther; 2011 Mar; 11(5):477-89. PubMed ID: 21263218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and indirect activation of eukaryotic elongation factor 2 kinase by AMP-activated protein kinase.
    Johanns M; Pyr Dit Ruys S; Houddane A; Vertommen D; Herinckx G; Hue L; Proud CG; Rider MH
    Cell Signal; 2017 Aug; 36():212-221. PubMed ID: 28502587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eukaryotic elongation factor 2 (eEF2) kinase/eEF2 plays protective roles against glucose deprivation-induced cell death in H9c2 cardiomyoblasts.
    Kameshima S; Okada M; Yamawaki H
    Apoptosis; 2019 Apr; 24(3-4):359-368. PubMed ID: 30737648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.
    Fu LL; Xie T; Zhang SY; Liu B
    Apoptosis; 2014 Oct; 19(10):1527-31. PubMed ID: 25023961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of eukaryotic elongation factor 2 (eEF2) by cyclin A-cyclin-dependent kinase 2 regulates its inhibition by eEF2 kinase.
    Hizli AA; Chi Y; Swanger J; Carter JH; Liao Y; Welcker M; Ryazanov AG; Clurman BE
    Mol Cell Biol; 2013 Feb; 33(3):596-604. PubMed ID: 23184662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.
    Comert Onder F; Siyah P; Durdagi S; Ay M; Ozpolat B
    RSC Med Chem; 2022 Jul; 13(7):840-849. PubMed ID: 35923718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling.
    Wang X; Regufe da Mota S; Liu R; Moore CE; Xie J; Lanucara F; Agarwala U; Pyr Dit Ruys S; Vertommen D; Rider MH; Eyers CE; Proud CG
    Mol Cell Biol; 2014 Nov; 34(22):4088-103. PubMed ID: 25182533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.
    Zhu H; Yang X; Liu J; Zhou L; Zhang C; Xu L; Qin Q; Zhan L; Lu J; Cheng H; Sun X
    Cell Stress Chaperones; 2015 Mar; 20(2):217-20. PubMed ID: 25248493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach.
    Preti D; Romagnoli R; Rondanin R; Cacciari B; Hamel E; Balzarini J; Liekens S; Schols D; Estévez-Sarmiento F; Quintana J; Estévez F
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1225-1238. PubMed ID: 30141353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
    Zhang B; Zou J; Zhang Q; Wang Z; Wang N; He S; Zhao Y; Naman CB
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.
    Chen Z; Gopalakrishnan SM; Bui MH; Soni NB; Warrior U; Johnson EF; Donnelly JB; Glaser KB
    J Biol Chem; 2011 Dec; 286(51):43951-43958. PubMed ID: 22020937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2.
    Xiao M; Xie J; Wu Y; Wang G; Qi X; Liu Z; Wang Y; Wang X; Hoque A; Oakhill J; Proud CG; Li J
    Cell Commun Signal; 2020 Feb; 18(1):25. PubMed ID: 32054489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells.
    Xie CM; Liu XY; Sham KW; Lai JM; Cheng CH
    Autophagy; 2014 Sep; 10(9):1495-508. PubMed ID: 24955726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
    Liu R; Proud CG
    Acta Pharmacol Sin; 2016 Mar; 37(3):285-94. PubMed ID: 26806303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation.
    Fu Q; Liu X; Li Y; Wang P; Wu T; Xiao H; Zhao Y; Liao Q; Song Z
    Molecules; 2022 Jul; 27(15):. PubMed ID: 35956836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.